• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确定用于报告腹膜假黏液瘤临床和放射学数据的最小数据集。

Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei.

作者信息

Patrick-Brown Thale D J H, Mohamed Faheez, Thrower Andrew, Torgunrud Annette, Cosyns Sarah, Canbay Emel, Villeneuve Laurent, Flatmark Kjersti, Brandl Andreas

机构信息

Department of Tumour Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Peritoneal Malignancy Institute, Basingstoke Hospital, Basingstoke, UK.

出版信息

Pleura Peritoneum. 2023 Mar 21;8(1):1-9. doi: 10.1515/pp-2022-0200. eCollection 2023 Mar.

DOI:10.1515/pp-2022-0200
PMID:37020469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10067554/
Abstract

OBJECTIVES

Pseudomyxoma peritonei (PMP) is a rare cancer currently affecting over 11,736 patients across Europe. Since PMP is so uncommon, collaboration between scientific centers is key to discovering the mechanisms behind the disease, efficient treatments, and targets pointing to a cure. To date, no consensus has been reached on the minimum data that should be collected during PMP research studies. This issue has become more important as biobanking becomes the norm. This paper begins the discussion around a minimum data set that should be collected by researchers through a review of available clinical trial reports in order to facilitate collaborative efforts within the PMP research community.

CONTENT

A review of articles from PubMed, CenterWatch, ClinicalTrials.gov and MedRxiv was undertaken, and clinical trials reporting PMP results selected.

SUMMARY

There is a core set of data that researchers report, including age and sex, overall survival, peritoneal cancer index (PCI) score, and completeness of cytoreduction, but after this, reports become variable.

OUTLOOK

Since PMP is a rare disease, it is important that reports include as large of a number of standardised data points as possible. Our research indicates that there is still much ground to cover before this becomes a reality.

摘要

目的

腹膜假黏液瘤(PMP)是一种罕见癌症,目前在欧洲影响着超过11,736名患者。由于PMP非常罕见,科学中心之间的合作是发现该疾病背后机制、有效治疗方法以及指向治愈的靶点的关键。迄今为止,关于PMP研究中应收集的最低数据尚未达成共识。随着生物样本库成为常态,这个问题变得更加重要。本文通过回顾现有的临床试验报告,开启了围绕研究人员应收集的最低数据集的讨论,以促进PMP研究界的合作。

内容

对来自PubMed、CenterWatch、ClinicalTrials.gov和MedRxiv的文章进行了回顾,并选择了报告PMP结果的临床试验。

总结

研究人员报告的有一组核心数据,包括年龄和性别、总生存期、腹膜癌指数(PCI)评分以及肿瘤细胞减灭的完整性,但在此之后,报告变得各不相同。

展望

由于PMP是一种罕见疾病,报告中包含尽可能多的标准化数据点非常重要。我们的研究表明,在这成为现实之前,仍有很多工作要做。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16f7/10067554/92b3d9d5177d/j_pp-2022-0200_fig_003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16f7/10067554/af1ebad32311/j_pp-2022-0200_fig_001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16f7/10067554/ad7e6391eb0e/j_pp-2022-0200_fig_002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16f7/10067554/92b3d9d5177d/j_pp-2022-0200_fig_003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16f7/10067554/af1ebad32311/j_pp-2022-0200_fig_001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16f7/10067554/ad7e6391eb0e/j_pp-2022-0200_fig_002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16f7/10067554/92b3d9d5177d/j_pp-2022-0200_fig_003.jpg

相似文献

1
Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei.确定用于报告腹膜假黏液瘤临床和放射学数据的最小数据集。
Pleura Peritoneum. 2023 Mar 21;8(1):1-9. doi: 10.1515/pp-2022-0200. eCollection 2023 Mar.
2
Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.使用 FDG-PET/CT(PET-PCI)改良腹膜癌指数预测腹膜假黏液瘤患者肿瘤分级和无进展生存期的影响。
Eur Radiol. 2019 Oct;29(10):5709-5716. doi: 10.1007/s00330-019-06102-1. Epub 2019 Mar 14.
3
Evaluation of the significance of pseudomyxoma peritonei patients based on the Peritoneal Surface Oncology Group International (PSOGI) classification.基于腹膜表面肿瘤国际协会(PSOGI)分类评估假性黏液瘤腹膜患者的意义。
Asian J Surg. 2021 Jun;44(6):848-853. doi: 10.1016/j.asjsur.2021.01.012. Epub 2021 Feb 20.
4
Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines.关于腹膜假黏液瘤的共识和争议:对已发表的共识声明和指南的综述。
Orphanet J Rare Dis. 2021 Feb 13;16(1):85. doi: 10.1186/s13023-021-01723-6.
5
Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department.腹膜假黏液瘤(PMP)及其治疗——单一外科科室20年的经验
Rozhl Chir. 2020 Spring;99(4):159-166. doi: 10.33699/PIS.2020.99.4.159-166.
6
The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.源自卵巢的假性黏液瘤腹膜转移的突变特征和预后指标。
Int J Cancer. 2021 Apr 15;148(8):2036-2047. doi: 10.1002/ijc.33460. Epub 2021 Jan 11.
7
Combined ultrasonography and CT for prognosis and predicting clinical outcomes of patients with pseudomyxoma peritonei.联合超声和 CT 对腹膜假性黏液瘤患者的预后和临床结局预测。
Eur Radiol. 2023 Apr;33(4):2800-2808. doi: 10.1007/s00330-022-09242-z. Epub 2022 Nov 23.
8
[A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].[65例阑尾源性早期腹膜假黏液瘤的单中心临床分析]
Zhonghua Zhong Liu Za Zhi. 2019 Sep 23;41(9):698-702. doi: 10.3760/cma.j.issn.0253-3766.2019.09.010.
9
FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei.氟代脱氧葡萄糖正电子发射断层扫描/对比增强计算机断层扫描有助于预测腹膜假黏液瘤的复发。
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1630-7. doi: 10.1007/s00259-016-3347-z. Epub 2016 Feb 24.
10
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.

本文引用的文献

1
The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.腹腔内热灌注化疗在细胞减灭术后假性黏液瘤中的作用。
JAMA Surg. 2021 Mar 1;156(3):e206363. doi: 10.1001/jamasurg.2020.6363. Epub 2021 Mar 10.
2
Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative.根治性手术和 HIPEC 术后并发症对生存的影响:美国 HIPEC 协作组的多机构分析。
Ann Surg Oncol. 2020 Dec;27(13):4980-4995. doi: 10.1245/s10434-020-08843-6. Epub 2020 Jul 21.
3
Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department.
腹膜假黏液瘤(PMP)及其治疗——单一外科科室20年的经验
Rozhl Chir. 2020 Spring;99(4):159-166. doi: 10.33699/PIS.2020.99.4.159-166.
4
Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method.采用新的统计方法估计欧洲假黏液瘤的患病率。
Ann Surg Oncol. 2021 Jan;28(1):252-257. doi: 10.1245/s10434-020-08655-8. Epub 2020 Jun 2.
5
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.阑尾来源的假性黏液瘤行细胞减灭术(CRS)和腹腔内热灌注化疗(HIPEC):单中心研究结果。
Updates Surg. 2020 Dec;72(4):1207-1212. doi: 10.1007/s13304-020-00788-5. Epub 2020 May 14.
6
Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment.阑尾肿瘤和腹膜假黏液瘤:文献综述及 PSOGI/EURACAN 诊断和治疗临床实践指南。
Eur J Surg Oncol. 2021 Jan;47(1):11-35. doi: 10.1016/j.ejso.2020.02.012. Epub 2020 Feb 28.
7
Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.阑尾来源的假性黏液瘤行细胞减灭术加腹腔内热灌注化疗后的围手术期安全性:单中心 254 例患者的经验。
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):600-606. doi: 10.1016/j.ejso.2020.01.017. Epub 2020 Jan 15.
8
Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.黏液性低级别阑尾肿瘤患者行细胞减灭术和腹腔热灌注化疗后发生腹膜转移的监测:5 年足够吗?多中心经验。
Ann Surg Oncol. 2020 Jan;27(1):147-153. doi: 10.1245/s10434-019-07678-0. Epub 2019 Aug 5.
9
Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.影响阑尾肿瘤来源的假性黏液瘤经细胞减灭术和腹腔热灌注化疗后长期生存的因素。
BJS Open. 2019 Feb 19;3(3):376-386. doi: 10.1002/bjs5.50134. eCollection 2019 Jun.
10
Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.腹腔热灌注化疗治疗假性黏液瘤腹膜转移的疗效分析:10 年经验。
J Gastrointest Surg. 2020 Apr;24(4):899-906. doi: 10.1007/s11605-019-04239-4. Epub 2019 May 14.